We provide experience-based consulting services for Biotech, Pharma and Medtech clients globally. Technical consulting, project management, strategy and management consulting, market and opportunity analyses are some of our core areas of expertise.go
Ventac Partners has a global network of Life Science investors in Europe, US and Asia as well as expertise in founding and growing companies on behalf of clients. Unlike other consulting agencies, we also found, actively manage, grow and help exit innovative Portfolio Companies co-owned with partners & investors.go
We offer extensive buy and sell-side transaction experience with a truly international reach in virtually all Life Science sectors. Our specialties include in- and out-licensing, mergers & acquisitions, business development and marketing collaborations in all continents.go
RhoVac AB, a Ventac portfolio company, reports that patient recruitment for the company’s on-going phase I/II study is now complete. The goal of the study is to evaluate the safety of RV001 vaccine and record potential immune responses in treated patients. For more information, please visit this link.
Idogen AB, a Ventac portfolio company, announced today that the company has been awarded funding of 2.9 million Euro from Horizon 2020, the EU Framework Programme for Research and Innovation, for the development of the company’s tolerogenic vaccine for the treatment of patients with severe hemophilia A and inhibitory antibodies against factor VIII. For more information, please visit this link.
Ventac Partners Mikael Oerum and Scott Woodward will be attending the BIO Annual Meeting in San Diego, USA.
Ventac portfolio companies, APIM Therapeutics and Avexxin, will be participating at BioEurope Spring Partnering meeting, in Barcelona, Spain (March 20-22, 2017).
Ventac Partners Melya Hughes Crameri will be attending the J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco (January 9-13)